MCL and miR-18b
Analysis of diagnostic mantle cell lymphoma (MCL) samples from the Nordic MCL2 (n= 74) and Nordic MCL3 (n = 94) clinical trials showed that overexpression of miR-18b identified patients with a poor prognosis.
All patients had been treated with rituximab plus chemotherapy as well as autologous stem cell transplantation. Compared with miR-92a and miR-378d, miR-18b was superior in predicting high risk. Based on these findings a new MIPI-B-miR prognosticator was created improving identification of high-risk patients compared with MIPI-B (MCL International prognostic index combined biologic index) with respect to cause-specific survival (p = 0.015), overall survival (p = 0.006) and progression-free survival (p <0.001). Read more here.